Method and system for preventing sore throat in humans

• US 10,668,014 B2
• Filed: 09/20/2018
• Issued: 06/02/2020
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik, Katherine Rose Kovarik
• Inventors: Kovarik, Joseph E., Kovarik, Katherine Rose
• Primary Examiner(s): Yu, Hong
• Application Number:
  US16/136,950
• Publication Number:
  US 20190015322A1
• Time in Patent Office: 621 Days
• CPC Class Codes: A61F 5/566 Intra-oral devices
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 49/0045 the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
• CPC Class Codes: A61K 49/0069 the agent being in a particular physical galenical form
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence

Abstract

A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human'"'"'s mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Claims

1. A bioadhesive strip for treating sore throat in a human being, comprising:

a solid strip having a first and second side, said first side having a surface comprising a pattern defined by a plurality of spaced apart features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns in at least a portion of said surface, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person'"'"'s mouth, wherein said strip is sized to extend over a majority of the soft palate, and wherein said strip includes one of an analgesic, and a lactic acid bacteria that coaggregates with S. pyogenes, and wherein a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system is employed to silence or to delete at least one virulence factor of S. pyogenes.

2. The strip of claim 1, wherein said strip includes at least one polymer selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.

3. The strip of claim 1 wherein said strip has an analgesic encapsulated inside a frangible capsule that may be broken by a person pressing against said strip with the person'"'"'s tongue.

4. The strip of claim 1 wherein said strip is non-dissolvable in a person'"'"'s mouth.

5. The strip of claim 1 wherein said strip is dissolvable in a person'"'"'s mouth within a period of 3 hours.

6. The strip of claim 1, wherein the strip comprises at least one encapsulated feature.

7. The strip of claim 1, wherein said strip further includes at least 200 mg of xylitol.

8. The strip as set forth in claim 1, wherein said strip comprises Prevotella bacteria.

11. The strip of claim 1, wherein the strip is dissolvable in a person'"'"'s mouth after one hour.

9. A bioadhesive solid strip for treating sore throat in a human being, comprising:

at least one surface of said strip having a pattern defined by a plurality of spaced apart features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns in at least a portion of said at least one surface, said strip having a first and second side, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person'"'"'s mouth, said strip having a length dimension of between 0.5 and 2 cm;

a surface area of between 0.25-1.5 square inches;

a weight of at least 30 mg; and

includes bacteria modified by a CRISPR-Cas or Cfp1 system.

10. The strip of claim 9, wherein the strip comprises S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors.

12. The strip of claim 9, wherein the strip comprises S. pyogenes that have been modified to remove or disable one or more virulence factors and wherein the S. pyogenes is encapsulated on the strip within a pouch or pocket.

13. The strip of claim 9, wherein the strip includes S. pyogenes that have been modified to render ineffective virulence factors in a manner effective to avoid sore throat progression.

14. The strip of claim 9, wherein the bacteria modified by a CRISPR-Cas or Cfp1 system are lactic acid bacteria that coaggregate with S. pyogenes.

15. The strip of claim 9, wherein said strip reduces the adhesion of S. pyogenes to an epithelial tissue of a person.

16. The strip of claim 9, wherein the strip has a thickness of between 100-400 microns thick and includes one of bacterial and helminth components.

17. The strip of claim 9, wherein said strip has an analgesic encapsulated inside a frangible capsule that may be broken by a person pressing against said strip with the person'"'"'s tongue.